Regulatory Filings • Jun 1, 2015
Regulatory Filings
Open in ViewerOpens in native device viewer
Breda, the Netherlands / Ghent, Belgium, 1 June 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Jefferies 2015 Global Healthcare Conference in New York City (NY, USA) on Tuesday, 2 June 2015 at 8:00 am EDT.
The presentation will be webcast live and can be accessed on the day viathis link. A replay of the webcast will be available on the Company's website, under the Reports & Presentations section, for 90 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
arGEN-X (ARGX) combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.
+32 (0)9 243 40 70 [email protected]
Citigate Dewe Rogerson +44 207 282 2948 [email protected]
Stern Investor Relations +1 212 362 1200 [email protected]
The contents of this announcement include statements that are, or may be deemed to be, "forwardlooking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X' actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. "Management's Discussion and Analysis of Financial Condition and Results of Operations"
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.